# FDA 483 - Takashi Kamezawa - December 05, 2025

Source: https://www.globalkeysolutions.net/records/483/takashi-kamezawa/8f1aae0a-a6a5-4fd8-a5d5-be3802fd648b

> FDA 483 for Takashi Kamezawa on December 05, 2025. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Takashi Kamezawa
- Inspection Date: 2025-12-05
- Product Type: drugs
- Office Name: Office of Inspections and Investigations
- Summary: An FDA inspection of Takashi Kamezawa, a clinical investigator in Kasugai, Aichi, Japan, revealed significant deviations from an investigational plan. The firm failed to conduct an investigation in accordance with the signed statement of investigator and investigational plan, specifically by enrolling subjects who were using prohibited concomitant medications. This non-compliance raises concerns about subject safety and data integrity within the clinical study.

## Related Officers

- [Raman K. Kaushal](https://www.globalkeysolutions.net/people/raman-k-kaushal/fbf1abb7-2303-433e-a56d-2622e29f62c8)

Company: https://www.globalkeysolutions.net/companies/takashi-kamezawa/233f5902-0fdf-4071-8579-12a9679622f8

Office: https://www.globalkeysolutions.net/offices/office-of-inspections-and-investigations/7dd0b904-a3df-46bc-a7b2-70ddb6f809c8